科研動(dòng)態(tài)

為評(píng)價(jià)重組流感病毒（H5+H7）二價(jià)滅活疫苗（H5N1 Re-8株+H7N9 H7-Re1株）對(duì)鵪鶉和鴿子的安全性及免疫效果，2017年12月—2018年6月，采用哈爾濱維科生物技術(shù)開發(fā)公司生產(chǎn)的重組流感病毒（H5+H7）二價(jià)滅活疫苗，對(duì)鵪鶉和肉鴿，在25日齡首免，46日齡二免（鵪鶉和肉鴿的劑量分別為0.3 mL和1 mL），觀察禽群臨床表現(xiàn)，定期采集血清測(cè)定抗體效價(jià)。結(jié)果顯示：鵪鶉首免后21 d，H5和H7亞型HI抗體效價(jià)均達(dá)到高峰，分別為（7.7±1.3）log2和（8.5±1.3）log2，抗體合格率大于70%的持續(xù)期約為35 d；二免后7 d，H5和H7亞型抗體效價(jià)均達(dá)到高峰，效價(jià)分別為（9.7±0.9）log2和（10.3±0.9）log2，H5和H7亞型抗體合格率大于70%的持續(xù)期分別約為147 d和175 d。鴿子首免后21 d，H5和H7抗體效價(jià)也均到達(dá)高峰，分別為（9.8±0.8）log2和（10.4±1.1）log2，兩種亞型抗體合格率大于70%的持續(xù)期均超過(guò)181 d；加強(qiáng)免疫后7 d，H5和H7抗體效價(jià)也均達(dá)到高峰，效價(jià)分別為（10.2±1.0）log2和（10.7±0.9）log2，189 d后效價(jià)分別為（5.4±1.3）log2和（6.1±1.5）log2，合格率分別為96.7%和100%。臨床觀察，未發(fā)現(xiàn)該疫苗有嚴(yán)重免疫不良反應(yīng)。結(jié)果表明，（H5+H7）二價(jià)滅活疫苗對(duì)鵪鶉和鴿子安全有效。生產(chǎn)中推薦：鵪鶉25日齡首免，46日齡和6月齡各加強(qiáng)免疫1次，劑量為0.3 mL；鴿子25日齡首免，以后每隔6個(gè)月加強(qiáng)免1次，劑量為1 mL。

Immunogenicity Study onBivalent Inactivated Vaccines of H5N1 and H7N9

Subtype Influenza in Quailsand Pigeons

In order to evaluate the safety and immuneeffects of the bivalent inactivated vaccine（H5N1 Re-8 + H7N9 H7-Re1 strain）of recombinant influenza virus（H5+H7）in quails and pigeons，the bivalent inactivated vaccines produced by HarbinWeike Biotechnology Development Company were immunized in quails and youngpigeons from December 2017 to June 2018. The dose for a quail/pigeon was 0.3/1mL in first immunization at 25 days of age and enhanced immunization at 46 daysof age respectively. The clinical manifestations of poultry flocks wereobserved and the titers of antibodies were determined by collecting serumsregularly. The results showed that the titers of anti-HI antibodies of H5 and H7subtypes reached peak values 21 days after first immunization in quails with（7.7±1.3）log2 and（8.5±1.3）log2 respectively. The duration of antibody eligibility exceeding 70%was about 35 days. The titers of anti-HI antibodies of H5 and H7 subtypesreached peak values 7 days after enhanced immunization with（9.7±0.9）log2 and（10.3±0.9）log2，respectively. The effect duration ofantibodies against H5 and H7 subtypes exceeding 70% were about 147 and 175 daysrespectively. The titers of H5 and H7 antibodies reached their peaks 21 daysafter first immunization in young pigeons with（9.8±0.8）log2 and（10.4±1.1）log2 respectively. The period when thequalification rates of the two subtypes of antibodies exceeded 70% was morethan 181 days. The titers of H5 and H7 antibodies reached their peaks 7 daysafter enhanced immunization with（10.2±1.0）log2 and（10.7±0.9）log2，respectively. After 189 days，the titers were（5.4±1.3）log2 and（6.1±1.5）log2 respectively，and the qualification rates were 96.7% and 100% respectively. Noserious side effects were found in clinical observation. The results showedthat（H5+H7）bivalent inactivated vaccine was safe and effectivefor quails and pigeons. Therefore，it was recommended that quails should be immunized at25 days of age，and they should receive enhanced immunes at46 days and 180 days at the dose of 0.3 mL. The pigeons should receive fistinoculation at 25 days of age，and enhanced immunizations every 6 months with the dose of 1 mL.

全文下載鏈接：

http://kns.cnki.net/kcms/detail/37.1246.S.20190222.0911.030.html?uid=WEEvREcwSlJHSldTTEYzU3EydDRPZTFBeXhDa29ZZ2ljVUtvTXF2T3dtND0=$9A4hF_YAuvQ5obgVAqNKPCYcEjKensW4IQMovwHtwkF4VYPoHbKxJw!!